Nucleic Acid-Based Nanoconstructs for the Treatment of Cancer

 描述（由申请人提供）：西北大学癌症纳米技术卓越中心（NU-CCNE），用于治疗癌症的基于核酸的纳米结构西北大学PI：Chad A. Mirkin和Leonidas Platanias关于癌症的遗传基础以及如何分析和治疗癌症，还有很多东西需要了解。目前的治疗方法无法提供针对个体患者的有效、靶向、精确的治疗。由于其新颖的化学、生物学和物理特性，基于核酸的纳米结构可用于进入特权细胞内环境，发现癌症生物学的新方面，并利用纳米结构-生物分子相互作用来创造有效的治疗选择。癌症纳米技术卓越中心的核酸为基础的纳米结构治疗癌症，总部设在西北大学（NU），提出探索这些巨大的可能性，通过应用一类新的纳米结构遗传结构-球形核酸 酸及其变体-用于脑癌和前列腺癌的研究和治疗。拟议的中心将有三个项目（一个基于发现和两个翻译），一个核心设施，和两个营利性合作伙伴联合起来，为癌症研究和治疗中令人生畏和复杂的问题提供新颖的基于纳米技术的解决方案。在首席研究员的指导下，Chad A. Mirkin和Leonidas Platanias博士的CCNE代表了NU罗伯特H。Lurie综合癌症中心（RHLCCC）和NU国际纳米技术研究所（IIN）。RHLCCC是一个NCI指定的，综合性的，以大学为基础的矩阵癌症中心，进行广泛的多学科基础，临床和人口科学研究，每年的校外资金超过1.67亿美元。NU国际纳米技术研究所（IIN）是一个伞式组织，它联合了NU的所有纳米技术研究和教育计划，目前代表了超过6亿美元的纳米技术研究和基础设施资金。在癌症研究和纳米技术取得的重大进展的基础上，在过去的九年里，在一个单一的大学框架内运作，NU-CCNE将优化集成和合作的密集水平，以创造一个加速的途径-从概念到临床试验-为纳米材料和纳米器件的发展，以克服癌症。

 DESCRIPTION (provided by applicant): Northwestern University Center of Cancer Nanotechnology Excellence (NU-CCNE) for Nucleic Acid-Based Nanoconstructs for the Treatment of Cancer Northwestern University PIs: Chad A. Mirkin and Leonidas Platanias Much still remains to be learned about the genetic basis of cancer and how it can be analyzed and treated. Current treatment methodologies fall short of providing efficacious, targeted, precision therapies geared towards the individual patient. Due to their novel chemical, biological, and physical properties, nucleic-acid based nanoconstructs can be used to gain access to privileged intracellular environments, discover new aspects of cancer biology, and exploit nanostructure-biomolecular interactions to create effective treatment options. The Center of Cancer Nanotechnology Excellence for Nucleic Acid-Based Nanoconstructs for the Treatment of Cancer, headquartered at Northwestern University (NU), proposes to explore these vast possibilities by applying a novel class of nanostructure genetic constructs - the spherical nucleic acid and variants of it - for the study and treatment of brain and prostate cancer. The proposed Center will feature three projects (one discovery-based and two translational), one core facility, and two for-profit partners united to provide novel nanotechnology-based solutions to daunting and complex issues in cancer research and treatment. Under the direction of Principal Investigators, Professor Chad A. Mirkin and Dr. Leonidas Platanias the CCNE represents an integrated partnership between the NU Robert H. Lurie Comprehensive Cancer Center (RHLCCC) and the NU International Institute for Nanotechnology (IIN). The RHLCCC is an NCI-designated, comprehensive, University-based, matrix cancer center conducting a broad range of multidisciplinary basic, clinical, and population science research with over $167 million dollar in annual extramural funding. The NU International Institute for Nanotechnology (IIN) is an umbrella organization which unites all of the nanotechnology research and educational programs at NU, and currently represents more than $600 million in funding for nanotechnology research and infrastructure. Building upon the significant advances in cancer research and in nanotechnology obtained at NU over the past nine years, and operating within the framework of a single university, the NU-CCNE will optimize the intensive level of integration and collaboration required to create an accelerated pathway-from conception to clinical trial-for development of nanomaterials and nanodevices to overcome cancer.